Biomarkers for prediction of response to neoadjuvant chemoradiation therapy in rectal cancer

摘要

The present invention relates to a biomarker for predicting the response to anticancer radiotherapy selected from the group consisting of CAMP (human cathelicidin antimicrobial peptide), LPCAT2 (Lysophosphatidylcholine acyltransferase 2) and AKR1B1 (Aldo-keto reductase family 1, member B1). Specifically, a composition for predicting response to anticancer radiotherapy; Prediction kit; It relates to a method of providing information for prediction. By using the biomarker of the present invention, the presence or absence of a reaction to anticancer radiation therapy of a rectal cancer patient can be predicted before surgery, which can greatly help in determining a treatment policy for a rectal cancer patient.